In December 2019, an outbreak caused by coronavirus disease 2019 (COVID-19) occurred in Wuhan, Hubei Province, China. As of March 22, 2020, a total of 306,506 COVID-19 cases were reported in more than a hundred countries worldwide. More than 12,000 patients died from infection of this new virus (named severe acute respiratory syndrome coronavirus 2 \[SARS-CoV-2\]), urging early identification and intervention for severe cases.

SARS-CoV-2, as a betacoronavirus, shares 88% of 2 bat-derived SARS-like coronaviruses and distances from SARS-CoV (around 79%) and Middle East respiratory syndrome coronavirus (around 50%).[@bib1] SARS and Middle East respiratory syndrome epidemics posed threats to global health due to high mortality rates of 9.6% for SARS-CoV and 34.4% for Middle East respiratory syndrome coronavirus globally.[@bib2] ^,^ [@bib3] Epidemiological data released by the Chinese Center for Disease Control and Prevention showed that 50,005 confirmed cases have been identified in Wuhan and 31,513 in mainland China except Wuhan as of March 22, 2020. The mortality rate of patients with COVID-19 was 5.0% in Wuhan, which was close to that in the world (4.2%) and much higher than that in mainland China except Wuhan (2.4%). This study aimed to describe and compare the epidemiologic, demographic, clinical, laboratory, and radiological characteristics as well as the complications, treatment, and outcomes of hospitalized patients with nonsevere and severe COVID-19. Potential risk factors for severe COVID-19 and factors associated with death in severe cases were analyzed to provide scientific data for relief in severe cases and reduce mortality.

Methods {#sec1}
=======

Data source {#sec1.1}
-----------

This study was an ambispective cohort study of consecutive hospitalized patients with COVID-19 enrolled at Sino-French New City Branch of Tongji Hospital, Huazhong University of Science and Technology in Wuhan from January 26, 2020, to February 5, 2020. The final date of follow-up was March 3, 2020. The Sino-French New City Branch of Tongji Hospital is one of the major nationally designated hospitals only providing medical care for adult patients with COVID-19 in Wuhan. All cases with COVID-19 enrolled in this study were diagnosed on the basis of World Health Organization interim guidance[@bib4] and the diagnostic and treatment guideline for COVID-19 issued by the Chinese National Health Committee (version 5). Detection of SARS-CoV-2 nucleic acids is described in text in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0010}.[@bib5] This study was approved by the Institutional Review Board of Tongji Hospital, Huazhong University of Science and Technology. Written informed consent was waived in light of the urgent need to collect data.

The epidemiologic and demographic data were obtained by face-to-face or telephonic interview. Clinical symptoms, laboratory, and radiological findings on admission as well as the complications, treatment, and outcomes during hospitalization were extracted from electronic medical records. Serum cytokine levels (IL-1β, IL-2R, IL-6, IL-8, IL-10, and TNF-α) were measured on admission. Patient data were cross-checked for consistency before final data entry and then entered into a computerized database.

The presence of underlying comorbidities was identified on the basis of *International Classification of Diseases, Revision 10* diagnostic codes. The complications of COVID-19 after admission were assessed, and the definitions are described in text in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0015}. Cardiac injury was one of the complications, which was defined as a serum hypersensitive cardiac troponin I level higher than 15.6 pg/mL without acute coronary symptoms or abnormal electrocardiogram. The clinical outcomes were classified into discharge from hospital, in-hospitalization, and death.

Severe COVID-19 was defined according to the 2019 clinical practice guideline from the Infectious Diseases Society of America and the American Thoracic Society for diagnosis and treatment of adults with community-acquired pneumonia.[@bib6] On the basis of whether or not requiring ventilatory support on admission, severe cases upon admission were divided into 2 cohorts, severely ill and critically ill cases.

Statistical analysis {#sec1.2}
--------------------

The descriptive statistics are median and interquartile range for continuous data. The statistics for categorical variables are counts and percentages. Mann-Whitney *U* test was performed for continuous variables, and the χ^2^ test and Fisher exact test were used for categorical variables as appropriate. Kruskal-Wallis test with Dunn's multiple comparison was used to compare across groups.

Multivariable binary logistic regression analyses were used to assess the association between age, sex, source of infection, underlying comorbidity, number of hospital visits, time from onset to hospitalization, days of fever preadmission, abnormal laboratory findings, and the dependent variable of severity of disease. The odds ratio (OR) along with the 95% CI were reported. Univariable and multivariable analyses to identify factors associated with death from COVID-19 in severe patients were performed by Cox proportional hazards regression model. Considering the total number of deaths (n = 87) in our study, 9 variables were chosen for multivariate Cox model on the basis of univariable analysis (*P* \< .05), previous findings, and clinical importance, including sex, age, laboratory findings (blood leukocyte count and lactose dehydrogenase \[LDH\]) on admission, the complications (cardiac injury and hyperglycemia), and drug therapy (corticosteroid, lopinavir/ritonavir, and umifenovir) during hospitalization. The hazard ratio (HR) along with the 95% CI were reported. A *P* value of less than .05 was regarded as statistically significant. All statistical analyses were performed using SPSS 25.0 for Windows (SPSS, Inc, Chicago, Ill). Detailed statistical analyses are presented in text and [Table E6](#appsec1){ref-type="sec"} in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0020}.

Results {#sec2}
=======

Epidemiologic and demographic characteristics {#sec2.1}
---------------------------------------------

A total of 549 patients with COVID-19 were enrolled, of whom 548 cases were included in the study. One case not meeting inclusion criteria was excluded because of inclusion criteria. Almost half the patients (49.1%, 269 of 548) were identified as severe cases and 50.9% (279 of 548) were nonsevere cases on admission; 68.7% (347 of 505) of cases were positive for SARS-CoV-2 nucleic acid test preadmission. Comparison of findings between nonsevere and severe cases in the patients with positive viral nucleic acid test preadmission showed essentially the similar differences to those in the total patients (see [Table E1](#appsec1){ref-type="sec"} in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0025}).

The epidemiologic and demographic characteristics are presented in [Table I](#tbl1){ref-type="table"} . Fifty-two (9.5%) of 546 patients got the infection in hospital. Forty-five (8.2%) of 547 patients were health care workers, and 67 (12.2%) patients were family members of health care workers. Nonsevere cases had a higher proportion of health care workers and family members than severe cases (*P* \< .001). The date of onset of the first reported case with COVID-19 was December 1, 2019.[@bib7] The median time from December 1, 2019, to the onset of COVID-19 was 54 days, ranging from 19 days to 63 days.Table IEpidemiologic, demographic, and clinical characteristics of hospitalized patients with COVID-19CharacteristicAll patients (n = 548)Nonsevere (n = 279)Severe (n = 269)*P* valueAge (y)60 (48-69)56 (44-66)65 (54-72).000 0-44107 of 548 (19.5%)75 of 279 (26.9%)32 of 269 (11.9%).000 45-64231 of 548 (42.2%)129 of 279 (46.2%)102 of 269 (37.9%) ≥65210 of 548 (38.3%)75 of 279 (26.9%)135 of 269 (50.2%)Male279 of 548 (50.9%)126 of 279 (45.2%)153 of 269 (56.9%).006Body mass index (kg/m^2^)24.7 (22.4-26.7)24.5 (22.4-26.0)25.3 (22.4-27.6).257Source of infections Household contact494 of 546 (90.5%)245 of 278 (88.1%)249 of 268 (92.9%).060 Hospital-acquired infections52 of 546 (9.5%)33 of 278 (11.9%)19 of 268 (7.1%)Disease risk Health care workers45 of 547 (8.2%)36 of 279 (12.9%)9 of 268 (3.4%).000 Family member of health care workers67 of 547 (12.2%)42 of 279 (15.1%)25 of 268 (9.3%) Not health care workers or their family members435 of 547 (79.5%)201 of 279 (72.0%)234 of 268 (87.3%)Time of onset (d)[∗](#tbl1fnlowast){ref-type="table-fn"}54 (51-56)54 (52-56)54 (51-56).394Time from onset to outpatient visit (d)3 (1-6)3 (1-5)4 (1-7).018 0-3283 of 522 (54.2%)158 of 270 (58.5%)125 of 252 (49.6%).044 \>3239 of 522 (45.8%)112 of 270 (41.5%)127 of 252 (50.4%)Time from onset to hospitalization (d)10 (7-12)9 (7-12)10 (7-12).035No. of hospital visits ≥2307 of 548 (56.0%)144 of 279 (51.6%)163 of 269 (60.6%).039Smoking history Never smokers452 of 544 (83.1%)238 of 279 (85.3%)214 of 265 (80.8%).051 Former smokers51 of 544 (9.4%)18 of 279 (14.7%)33 of 265 (12.5%) Current smokers41 of 544 (7.5%)23 of 279 (8.2%)18 of 265 (6.8%)Underlying comorbidity Chronic obstructive pulmonary disease17 of 548 (3.1%)4 of 279 (1.4%)13 of 269 (4.8%).026 Asthma5 of 548 (0.9%)2 of 279 (0.7%)3 of 269 (1.1%).681 Tuberculosis9 of 548 (1.6%)5 of 279 (1.8%)4 of 269 (1.5%)1.000 Diabetes83 of 548 (15.1%)31 of 279 (11.1%)52 of 269 (19.3%).009 Hypertension166 of 548 (30.3%)62 of 279 (22.2%)104 of 269 (38.7%).000 Coronary heart disease34 of 548 (6.2%)6 of 279 (2.2%)28 of 269 (10.4%).000 Hepatitis B5 of 548 (0.9%)3 of 279 (1.1%)2 of 269 (0.7%)1.000 Chronic kidney disease10 of 547 (1.8%)4 of 278 (1.4%)6 of 269 (2.2%).539 Tumor24 of 513 (4.7%)10 of 256 (3.9%)14 of 257 (5.5%).531Previous drugs use ACEI/ARB42 of 545 (7.7%)23 of 279 (8.2%)19 of 266 (7.1%).748 Systemic corticosteroids6 of 548 (1.1%)4 of 279 (1.4%)2 of 269 (0.7%).686 Inhaled corticosteroids5 of 548 (0.9%)3 of 279 (1.1%)2 of 269 (0.7%)1.000 Antibiotics7 of 548 (1.3%)3 of 279 (1.1%)4 of 269 (1.5%).720 Anticoagulants16 of 547 (2.9%)5 of 278 (1.8%)11 of 269 (4.1%).132 Immunosuppressant drugs5 of 548 (0.9%)3 of 279 (1.1%)2 of 269 (0.7%)1.000 Antiviral drugs2 of 548 (0.4%)1 of 279 (0.4%)1 of 269 (0.4%)1.000Symptoms Fever at preadmission476 of 500 (95.2%)248 of 260 (95.4%)228 of 240 (95.0%)1.000 Highest temperature (°C)38.8 (38.2-39)38.8 (38-39)38.8 (38.4-39).416 Duration (d)9 (6-11)8.5 (6-11)10 (7-12).031 Fatigue258 of 548 (47.1%)128 of 279 (45.9%)130 of 269 (48.3%).608 Sore throat28 of 548 (5.1%)17 of 279 (6.1%)11 of 269 (4.1%).335 Cough415 of 548 (75.7%)212 of 279 (76.0%)203 of 269 (75.5%).921 Chest pain41 of 548 (7.5%)25 of 279 (9.0%)16 of 269 (6.0%).197 Dyspnea310 of 548 (56.6%)112 of 279 (40.1%)198 of 269 (73.6%).000 Chest tightness162 of 425 (38.1%)86 of 245 (42.2%)76 of 180 (38.1%).157 Dizziness56 of 548 (10.2%)29 of 279 (10.4%)27 of 269 (10.0%)1.000 Confusion17 of 548 (3.1%)1 of 279 (0.4%)16 of 269 (6.0%).000 Headache62 of 548 (11.3%)37 of 279 (13.3%)25 of 269 (9.3%).177 Myalgia111 of 548 (20.3%)62 of 279 (22.2%)49 of 269 (18.2%).288 Vomiting45 of 548 (8.2%)25 of 279 (9.0%)20 of 269 (7.4%).537 Diarrhea179 of 548 (32.7%)94 of 279 (33.7%)85 of 269 (31.6%).649 Abdominal pain16 of 548 (2.9%)4 of 279 (1.4%)12 of 269 (4.5%).043Administration of systemic corticosteroids preadmission64 of 540 (11.9%)22 of 274 (8.0%)42 of 266 (15.8%).007 Duration (d)1 (0-3)0 (0-1)2.5 (1-4).000 Cumulative dose[†](#tbl1fndagger){ref-type="table-fn"} (mg)50 (0-150)0 (0-66.7)100 (50-187.5).000Administration of antiviral drugs preadmission Lopinavir/ritonavir13 of 541 (2.4%)10 of 276 (3.6%)3 of 265 (1.1%).089 Umifenovir177 of 538 (32.9%)113 of 274 (41.2%)64 of 264 (24.2%).000 Oseltamivir189 of 538 (35.1%)112 of 274 (40.9%)77 of 264 (29.2%).005 Ribavirin8 of 538 (1.5%)2 of 274 (0.7%)6 of 264 (2.3%).169[^2][^3][^4][^5]

The median age of study population was 60 years (interquartile range, 48-69), ranging from 18 years to 95 years, of whom 210 (38.3%) were aged 65 years or older. The patients aged 65 years or older in severe cases were almost twice as nonsevere cases of the same age (50.2% vs 26.9%; *P* \< .001). Slightly more than half (50.9%) of all patients were male, and the proportion of males in severe cases was higher than in nonsevere cases (56.9% vs 45.2%; *P =* .006).

Clinical characteristics on admission {#sec2.2}
-------------------------------------

About 19.2% of patients with severe COVID-19 were smokers ([Table I](#tbl1){ref-type="table"}). Compared with nonsevere cases, severe cases exhibited more comorbidities, including chronic obstructive pulmonary disease (4.8% vs 1.4%; *P* = .026), coronary heart disease (10.4% vs 2.2%; *P* \< .001), hypertension (38.7% vs 22.2%; *P* \< .001), and diabetes (19.3% vs 11.1%; *P* = .009), respectively. Only 5 cases of asthma (0.9%) were identified in the total population. Forty-two (7.7%) of 545 patients regularly took angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers; no significant difference was found between nonsevere and severe cases.

Most patients reported at least 1 of the following symptoms: fever (95.2%), fatigue (47.1%), sore throat (5.1%), cough (75.5%), chest pain (7.5%), dyspnea (56.6%), chest tightness (38.1%), dizziness (10.2%), confusion (3.1%), headache (11.3%), myalgia (20.3%), vomiting (8.2%), diarrhea (32.7%), and abdominal pain (2.9%). Six patients were asymptomatic and diagnosed by computed tomography (CT) screening. Duration of fever preadmission was significantly longer among severe cases than among nonsevere cases (*P =* .031). Severe cases experienced longer duration from onset to outpatient visit and longer duration from onset to hospitalization compared with nonsevere cases (*P* = .018 and *P* = .035, respectively). Sixty-four (11.9%) of 540 patients were treated with corticosteroids delivered by oral or intravenous preadmission. A total of 304 (56.5%) of 538 patients had received at least 1 of the following antiviral medications: umifenovir (32.9%), oseltamivir (35.1%), lopinavir/ritonavir (2.4%), and ribavirin (1.5%).

Radiographic and laboratory findings on admission {#sec2.3}
-------------------------------------------------

CT scans for 461 patients were evaluated preadmission, and showed multilobar pulmonary infiltrates in 436 patients ([Table II](#tbl2){ref-type="table"} ). The median time from onset to pneumonia diagnosed by CT scan was 4 days. On admission, oxygen saturation less than 93.1% on room air presented in 33.3% of all patients, of whom 163 (89%) were severe cases; 90.2% of all patients experienced lymphopenia (\<1500 cells/mm^3^), and 29.1% of all patients had thrombocytopenia (\<150,000 cells/mm^3^). Compared with nonsevere cases, inflammation-related marker levels (high sensitivity C-reactive protein, erythrocyte sedimentation rate, and ferritin) were significantly higher in severe cases. The levels of procalcitonin, globulin, LDH, NT-proB-type natriuretic peptide, d-dimer, alanine aminotransferase, aspartate aminotransferase, total bilirubin, conjugated bilirubin, blood urea nitrogen, and creatinine were elevated in 9.5%, 40.4%, 73.6%, 27.5%, 67.4%, 23.1%, 33.1%, 4.4%, 9.2%, 15.8%, and 27.1% of all patients, respectively. Serum cytokine levels of IL-2R, IL-6, IL-10, and TNF-α were significantly higher in severe patients than in nonsevere patients (all *P \<* .01).Table IIRadiographic and laboratory findings of patients with COVID-19FindingsAll patients (n = 548)Nonsevere (n = 279)Severe (n = 269)*P* valueCT findings preadmission Negative4 of 461 (0.9%)4 of 228 (1.8%)0.032 Unilobar lesion21 of 461 (4.6%)14 of 228 (6.1%)7 of 233 (3.0%) Multilobar lesion436 of 461 (94.6%)210 of 228 (92.1%)226 of 233 (97.0%)Time from onset to pneumonia diagnosed by CT scan (d)4 (2-7)4 (2-6)4 (2-7).258SARS-CoV-2 nucleic acid test[∗](#tbl2fnlowast){ref-type="table-fn"} Positive347 of 505 (68.7%)180 of 270 (66.7%)167 of 235 (71.1%).503 Suspected positive41 of 505 (8.1%)22 of 270 (8.1%)19 of 235 (8.1%) Negative117 of 505 (23.2%)68 of 270 (25.2%)49 of 235 (20.9%)Oxygen saturation (%) ≤93182 of 546 (33.3%)19 of 278 (6.8%)163 of 268 (60.8%).000 \>93364 of 546 (66.7%)259 of 278 (93.2%)105 of 268 (39.2%)Blood leukocyte count (×10⁹/L) \>1063 of 542 (11.6%)8 of 275 (2.9%)55 of 267 (20.6%).000 \<4130 of 542 (24.0%)84 of 275 (30.5%)46 of 267 (17.23%).000Neutrophil count (×10⁹/L) \>6.5118 of 542 (21.8%)22 of 275 (8.0%)96 of 267 (36.0%).000 ≤2.067 of 542 (12.4%)50 of 275 (18.2%)17 of 267 (6.4%).000Lymphocyte count (×10⁹/L) \<1.5489 of 542 (90.2%)234 of 275 (85.1%)255 of 267 (95.5%).000 ≤0.585 of 542 (15.7%)21 of 275 (7.6%)64 of 267 (24.0%).000Platelet count \<150 × 10⁹/L157 of 539 (29.1%)68 of 274 (24.8%)89 of 265 (33.6%).029High sensitive C-reactive protein (mg/L) \>10460 of 540 (85.2%)205 of 272 (75.4%)255 of 268 (95.2%).000 \>100138 of 540 (25.6%)40 of 272 (14.7%)98 of 268 (36.6%).000Procalcitonin \>0.5 ng/mL46 of 486 (9.5%)3 of 249 (1.43%)43 of 237 (18.9%).000Erythrocyte sedimentation rate \>20 mm/h377 of 518 (72.8%)179 of 264 (67.8%)198 of 254 (78.0%).010Ferritin \>500 μg/L211 of 313 (67.4%)95 of 171 (55.9%)116 of 142 (81.7%).000D-dimer \>1 mg/L227 of 501 (45.3%)78 of 254 (31.1%)149 of 247 (56.4%).000NT-proB-type natriuretic peptide \>500 pg/L92 of 335 (27.5%)17 of 136 (13.3%)75 of 199 (37.9%).000LDH (U/L) \>250393 of 534 (73.6%)162 of 272 (59.6%)231 of 262 (88.2%).000 \>445133 of 534 (24.9%)25 of 272 (9.2%)108 of 262 (41.2%).000Globulin \>35 g/L218 of 540 (40.4%)88 of 275 (32.0%)130 of 265 (49.1%).000Albumin ≤35 g/L320 of 541 (59.1%)126 of 275 (45.8%)194 of 266 (72.9%).000Alanine aminotransferase \>40 U/L125 of 541 (23.1%)61 of 275 (22.3%)64 of 266 (24.1%).683Aspartate aminotransferase \>40 U/L179 of 540 (33.1%)64 of 275 (23.3%)115 of 265 (43.4%).000Total bilirubin \>21 μmol/L24 of 541 (4.4%)7 of 275 (2.3%)17 of 266 (6.4%).036Conjugated bilirubin \>8 μmol/L50 of 541 (9.2%)17 of 275 (6.3%)33 of 266 (12.6%).017Blood urea nitrogen \>7.5 mmol/L85 of 539 (15.8%)18 of 273 (6.6%)67 of 266 (25.2%).000Creatinine \>85 μmol/L146 of 539 (27.1%)61 of 273 (22.3%)85 of 266 (32.0%).015IL-1β \>5 ng/L51 of 306 (16.7%)34 of 170 (20.0%)17 of 136 (12.5%).091IL-2R \>710 U/mL164 of 309 (53.1%)73 of 171 (42.7%)91 of 138 (65.9%).000IL-6 \>7 ng/L221 of 312 (70.8%)107 of 175 (61.1%)114 of 137 (83.2%).000IL-8 \>62 ng/L24 of 309 (7.8%)10 of 171 (5.9%)14 of 137 (10.1%).200IL-10 \>9.1 ng/L83 of 307 (27.0%)34 of 170 (20.0%)49 of 170 (35.8%).003TNF-α \>8.1 ng/L182 of 309 (58.9%)89 of 171 (52.1%)93 of 138 (67.4%).008Proteinuria200 of 330 (60.6%)98 of 193 (50.8%)102 of 137 (74.5%).000[^6][^7][^8]

Subgroup analysis {#sec2.4}
-----------------

Of the 269 severe cases, 46 were classified as critically ill for requiring respiratory support. Compared with severely ill cases, the time from December 1, 2019, to onset was shorter and the time from onset to outpatient visit was longer in critically ill cases (see [Table E2](#appsec1){ref-type="sec"} in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0030}). There were no significant differences in age and underlying comorbidities between severely ill and critically ill cases. More abnormal laboratory findings (such as high leukocyte, high procalcitonin, high NT-proB-type natriuretic peptide, high LDH, high d-dimer, low albumin, and high creatinine) were observed in critically ill cases compared with severely ill cases (all *P* \< .05). About 34.1% of critically ill patients received systemic corticosteroids preadmission, which was significantly higher than that in severely ill cases (12.2%; *P* \< .001).

Compared with nonsevere cases, systemic corticosteroid use preadmission was more common in severe cases, with larger cumulative dose and longer duration (*P =* .007, *P \<* .001, *P \<* .001, respectively). Stratification of patients by corticosteroid exposure is presented in [Table E3](#appsec1){ref-type="sec"} in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0035}. Severe patients treated with corticosteroids had higher LDH level compared with severe patients without corticosteroid use preadmission (*P \<* .05).

Nonsevere cases were more likely to receive antiviral drugs preadmission, including umifenovir and oseltamivir (*P \<* .001 and *P =* .005, respectively). In the severe case subgroup, the patients receiving umifenovir were younger than those without umifenovir use (*P \<* .05). A comparison of baseline demographic and clinical characteristics between patients with and without antiviral drug use revealed no marked difference in oxygen saturation or laboratory findings in both nonsevere and severe case subgroups (see [Tables E4](#appsec1){ref-type="sec"} and [E5](#appsec1){ref-type="sec"} in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0040}).

Risk factors for severe cases on admission {#sec2.5}
------------------------------------------

In the final logistic regression model, variables such as age 65 years or more (OR, 2.2; 95% CI, 1.5-3.5), hypertension (OR, 2.0; 95% CI, 1.3-3.2), LDH more than 445 U/L (OR, 4.4; 95% CI, 2.6-7.6), and d-dimer more than 1 mg/L (OR, 2.2; 95% CI, 1.4-3.3) were significantly associated with cases with severe COVID-19 ([Fig 1](#fig1){ref-type="fig"} ).Fig 1The effect of various potential risk factors on patients with severe COVID-19 at admission.

Complications, treatment, and clinical outcomes during hospitalization and follow-up {#sec2.6}
------------------------------------------------------------------------------------

In the follow-up period, the complications of COVID-19 were assessed, including acute respiratory distress syndrome (ARDS) (38.3%), cardiac injury (21.7%), liver dysfunction (19.3%), acute kidney injury (17.3%), bacteremia (7.7%), diffuse intravascular coagulation (7.7%), and hyperglycemia (33.2%) ([Table III](#tbl3){ref-type="table"} ). All the above-mentioned complications were more common in severe cases, compared with nonsevere cases (all *P \<* .05).Table IIIComplications and treatment during hospitalization and clinical outcomes of patients with COVID-19Complications and treatmentAll patients (n = 548)Nonsevere (n = 279)Severe (n = 269)*P* valueComplications ARDS210 of 548 (38.3%)27 of 279 (9.7%)183 of 269 (68.0%).000 Cardiac injury119 of 548 (21.7%)25 of 279 (9.0%)94 of 269 (34.9%).000 Liver dysfunction106 of 548 (19.3%)44 of 279 (15.8%)62 of 269 (23.0%).040 Acute kidney injury95 of 548 (17.3%)33 of 279 (11.8%)62 of 269 (23.0%).001 Bacteremia42 of 548 (7.7%)4 of 279 (1.4%)38 of 269 (14.1%).000 DIC42 of 548 (7.7%)5 of 279 (1.8%)37 of 269 (13.8%).000 Hyperglycemia182 of 548 (33.2%)60 of 279 (21.5%)122 of 269 (45.4%).000Administration of systemic corticosteroids341 of 548 (62.2%)145 of 279 (52.0%)196 of 269 (72.9%).000 Duration (d)4 (0-11)1 (0-10)5 (0-12).000 Cumulative dose (mg)200 (0-450)50 (0-400)295 (0-575).000Administration of antiviral drugs Lopinavir/ritonavir164 of 548 (29.9%)91 of 279 (32.6%)73 of 269 (27.1%).163 Umifenovir401 of 548 (73.2%)222 of 279 (79.6%)179 of 269 (66.5%).001 Oseltamivir221 of 548 (40.3%)127 of 279 (45.5%)94 of 269 (34.9%).015 Ribavirin29 of 548 (5.3%)8 of 279 (2.9%)21 of 269 (7.8%).012 IFN-α nebulization168 of 548 (30.7%)97 of 279 (34.8%)71 of 269 (26.4%).041Intravenous immunoglobulin213 of 548 (38.9%)103 of 279 (36.9%)110 of 269 (40.9%).381Vasopressor79 of 548 (14.4%)5 of 279 (1.8%)74 of 269 (27.5%).000Oxygen therapy355 of 548 (64.8%)131 of 279 (47.0%)224 of 269 (83.3%).000 Nasal cannula or mask228 of 548 (41.6%)118 of 279 (42.3%)110 of 269 (40.9%).000 High-flow oxygen therapy24 of 548 (4.4%)2 of 279 (0.7%)22 of 269 (8.2%) Noninvasive mechanical ventilation78 of 548 (14.2%)10 of 279 (3.6%)68 of 269 (25.3%) Invasive mechanical ventilation25 of 548 (4.6%)1 of 279 (0.4%)24 of 269 (8.9%)Continuous renal replacement therapy2 of 548 (0.4%)02 of 269 (99.3%).241Clinical outcomes Discharge from hospital287 of 545 (52.7%)202 of 277 (72.9%)85 of 268 (31.7%).000 In-hospitalization168 of 545 (30.8%)72 of 277 (26.0%)96 of 268 (35.8%) Death90 of 545 (16.5%)3 of 277 (1.1%)87 of 268 (32.5%)[^9][^10]Table IVUnadjusted and adjusted Cox proportional hazards regression model for death among patients with severe COVID-19VariableUnadjusted HR95% CI*P* valueAdjusted HR95% CI*P* valueSex, male vs female1.961.24-3.11.0041.721.05-2.82.032Age, ≥65 y vs \<65 y1.691.09-2.59.0181.721.09-2.73.021Blood leukocyte count, \>10 × 10⁹/L vs ≤10 × 10⁹/L3.852.50-5.93.0002.041.26-3.31.004LDH, \> 445 U/L vs ≤445 U/L3.942.48-6.28.0002.001.21-3.30.007Complications Cardiac injury3.892.52-6.01.0002.921.80-4.76.000 Hyperglycemia2.491.61-3.87.0001.771.11-2.84.017Treatment Corticosteroids.000.000 No steroid (reference) Low dose[∗](#tbl4fnlowast){ref-type="table-fn"}1.070.57-2.01.8251.260.61-2.580.534 High dose[†](#tbl4fndagger){ref-type="table-fn"}3.321.85-5.97.0003.501.79-6.86.000 Lopinavir/ritonavir0.260.13-0.52.0000.430.21-0.89.022 Umifenovir0.460.30-0.71.0000.540.34-0.84.007[^11][^12][^13]

Antiviral drugs were used specifically to treat COVID-19 during hospitalization, including lopinavir/ritonavir (29.9%), umifenovir (73.2%), oseltamivir (40.3%), ribavirin (5.3%), and IFN-α nebulization (30.7%). Antiviral drug use was more common in nonsevere cases than in severe cases except for ribavirin. A total of 341 (62.2%) of 548 patients were administered systemic corticosteroids, with a medium duration of 4 days and medium cumulative dose equivalent to 200 mg prednisone. Of the 548 patients, 355 (64.8%) required oxygen support during hospitalization, including nasal cannula or mask (41.6%), high-flow oxygen therapy (4.4%), noninvasive mechanical ventilation (14.2%), and invasive mechanical ventilation (4.6%).

Mortality rates for COVID-19 were estimated to be 1.1% (3 of 277) in nonsevere patients and 32.5% (87 of 268) in severe cases during the average 32 days of follow-up; 72.9% of nonsevere cases and 31.7% of severe cases were discharged from hospital.

Factors associated with death in severe cases {#sec2.7}
---------------------------------------------

Multivariable Cox proportional hazards regression analysis revealed that male sex (adjusted HR, 1.7; 95% CI, 1.0-2.8), age 65 years or more (adjusted HR, 1.7; 95% CI, 1.1-2.7), blood leukocyte count more than 10 cells/mm^3^ (adjusted HR, 2.0; 95% CI, 1.3-3.3), and LDH more than 445 U/L (adjusted HR, 2.0; 95% CI, 1.2-3.3) at admission, cardiac injury (adjusted HR, 2.9; 95% CI, 1.8-4.8), hyperglycemia (adjusted HR, 1.8; 95% CI, 1.1-2.8), and administration of high-dose corticosteroids (adjusted HR, 3.5; 95% CI, 1.8-6.9) during hospitalization were significant risk factors associated with death in cases with severe COVID-19 ([Table IV](#tbl4){ref-type="table"}). Lopinavir/ritonavir (adjusted HR, 0.4; 95% CI, 0.2-0.9) and umifenovir (adjusted HR, 0.5; 95% CI, 0.3-0.8) were associated with lower death in patients with severe COVID-19. The adjusted Kaplan-Meier estimates of survival for sex, age, leukocyte, LDH, corticosteroid use, lopinavir/ritonavir use, and umifenovir use are shown in [Figs E1-E7](#appsec1){ref-type="sec"} in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0045}.

Discussion {#sec3}
==========

This study provided comprehensive data on the epidemiologic, demographic, clinical, laboratory, and radiological characteristics as well as the complications, treatment, and outcomes of hospitalized patients with nonsevere and severe COVID-19 in Wuhan. Almost half the patients in this study were identified as severe cases, which may differ from the results of the previous studies.[@bib8] The proportion of patients aged 65 years or more was higher in our study than in Nanshan Zhong's study (38.8% vs 15.1%, respectively).[@bib9] The time from December 1, 2019, to the onset of disease in most patients was longer than 50 days. During mid-January to early February, Wuhan experienced the highest peak of COVID-19 outbreak, with a family cluster and high prevalence of COVID-19 in older adults. Longer wait for access to medical care was observed in severe cases compared with nonsevere cases. More than half the patients experienced at least 2 hospital visits, which may have increased the risk of nosocomial transmission events. Diagnosis and treatment may have been delayed because of the long wait for access to medical care. Patients with severe COVID-19 likely developed ARDS and died of respiratory failure. Although there are currently no effective antiviral drugs for SARS-CoV-2, prompt identification and early respiratory support would provide relief in severe cases and reduce mortality. The severity of disease in patients with initial positive nucleic acid test result was similar to that of all patients with COVID-19. We thus propose that urgent timely diagnosis is crucial, and that early intervention should not be delayed on the basis of the nucleic acid test.

There are 6 coronavirus species currently known to cause human infection. SARS-CoV-2 was most closely related to SARS-CoV through phylogenetic analysis and was revealed to share a similar receptor, angiotensin-converting enzyme 2 (ACE 2), to SARS-CoV.[@bib1] This fact hints that COVID-19 may partly mimic SARS infection. The autopsy results of patients with SARS showed that high levels of proinflammatory cytokines were expressed in ACE 2--expressing cells infected by SARS-CoV.[@bib10] Plasma cytokine profiles of patients with SARS showed T~H~1-dominated responses with markedly elevated proinflammatory cytokine levels (INF-γ, IL-1β, IL-6, IL-8, IL-12, and TNF-α) and were associated with the development of ARDS.[@bib11], [@bib12], [@bib13] In our study, patients with severe COVID-19 had significantly higher levels of T~H~1 cytokines (IL-6 and TNF-α) and a higher incidence rate of ARDS, compared with nonsevere cases. Interestingly, the prevalence of asthma in patients with COVID-19 (0.9%) in our study was markedly lower than that reported in the adult population of Wuhan (6.4%).[@bib14], [@bib15], [@bib16] We thus speculate that T~H~2 immune response in patients with asthma may counter the inflammation process induced by SARS-CoV-2 infection. Further studies are required to characterize the immune response and inflammation features of COVID-19.

Most severe patients showed rapid progression and multiple organ dysfunction. The median time from onset to pneumonia diagnosed by CT scan was only 4 days. Approximately one-third of the patients experienced gastrointestinal symptoms. During hospitalization, a substantial proportion of patients presented cardiac injury, liver and kidney dysfunction, and hyperglycemia. It was proved that the fecal and urine samples and rectal swabs of patients with COVID-19 were positive for SARS-CoV-2 nucleic acids.[@bib9] ACE 2 was reported to be expressed in small intestinal epithelial cells, cholangiocytes, and the pancreas,[@bib17], [@bib18], [@bib19] indicating that SARS-CoV-2 infection may induce the multiorgan injury in patients with COVID-19. The shorter duration from December 1, 2019, to onset in critically ill cases than that in severely ill cases may reflect a higher virulence of SARS-CoV-2, or earlier onset of COVID-19.

The risk factors for severity identified in this study included age, high LDH level, and high d-dimer level, consistent with those in previous reports.[@bib15] ^,^ [@bib20] However, different from the findings of previous studies,[@bib21] hypertension was the only comorbidity associated with the severity of COVID-19 after adjustment for age, sex, and smoking status. The distinct features of pneumonia and high severity in patients with COVID-19 in this study may lead to this difference from previous reports. ACE 2, a gateway to SARS, was reported to be a protective factor against SARS-CoV--induced lung injury.[@bib22] ^,^ [@bib23] The association between ACE 2 expression and hypertension was confirmed in a previous study.[@bib24] This fact may partly explain the high prevalence of severe COVID-19 in patients with hypertension. LDH has been recognized as a marker for severe prognosis in various diseases, including cancer and infection.[@bib25] The high LDH level in COVID-19 in severe cases suggested that LDH may be associated with lung injury and tissue damage, warranting an investigation for the potential mechanism.

This study evaluated preadmission medications for patients with severe COVID-19. Although the proportion of nonsevere cases in patients receiving oseltamivir was higher than that in patients without oseltamivir use, stratification analysis showed that there was no significant difference in hypoxia between patients with and without oseltamivir use either in the severe case subgroup or in the nonsevere case subgroup. Therefore, oseltamivir use may just be an indicator of disease severity. The patients receiving umifenovir were younger than those without umifenovir use, indicating that younger patients may have easier access to drugs or prefer umifenovir.

Older age, leukocytosis, and high LDH level were reported to be risk factors associated with in-hospital death in previous studies.[@bib20] ^,^ [@bib26] ^,^ [@bib27] The present study also revealed that hyperglycemia was related with increased mortality in patients with COVID-19. The prevalence of hyperglycemia may be associated with underlying diabetes and corticosteroid therapy. However, the localization of ACE 2 expression in the pancreas in patients with SARS was reported to damage islets, resulting in hyperglycemia[@bib19]; this finding suggested that hyperglycemia may also be an indicator of severe COVID-19.

This study indicated that corticosteroid use was more common in severe cases than in nonsevere cases and that high-dose corticosteroid use was related to high risk of death in patients with severe COVID-19. High-dose steroid use may be an indicator of disease severity rather than a predisposing factor. In a previous study, treatment with methylprednisolone was shown to be beneficial for patients with COVID-19 who developed ARDS.[@bib20] However, critically ill cases had more signs of infection and abnormal laboratory findings, including high leukocyte, high procalcitonin, high d-dimer, low albumin, and high creatinine levels. High-dose corticosteroids should be used with caution in critically ill patients to avoid aggravating complications.

A recent study by Cao et al[@bib28] showed that lopinavir/ritonavir treatment offered no significant benefit over standard care for hospitalized adult patients with COVID-19. Cao et al's study also reported that lopinavir/ritonavir led to a shorter median time to clinical improvement than standard care (HR, 1.39; 95% CI, 1.00-1.91) in a modified intention-to-treat analysis. Compared with Cao et al's study, the severity of patients was more serious and lopinavir/ritonavir treatment was associated with a lower risk of death in patients with severe COVID-19 in this study. However, our study was an observational study; thus, the benefit of lopinavir/ritonavir for patients with severe COVID-19 needs to be further confirmed.

There were limitations to the current study. First, epidemiological data were collected respectively and recall bias might have occurred. Second, missing data on some variables, such as detailed information of CT scan, may cause bias in the estimation and reduce the representativeness of the samples. Third, laboratory findings were measured on admission and may indicate the severity of COVID-19. The causal relationship between abnormal laboratory findings and severity could not be determined. Fourth, this study was an observational study with limitations in terms of evaluating the efficacy of corticosteroids and antiviral drugs. Finally, the absence of comparative data from patients with COVID-19 not admitted or from other critically ill patients was a limitation of this study.

Conclusions {#sec3.1}
-----------

The COVID-19 outbreak has caused widespread concern and has threatened the global public health security. Recent evidence of possible fecal-oral transmission of the SARS-CoV-2 infection, asymptomatic infection,[@bib8] ^,^ [@bib29] ^,^ [@bib30] and positive result for SARS-CoV-2 test in recovered patients[@bib31] warrant aggressive measures to suppress and prevent the pandemic from spreading, such as hygiene maintenance, early screening and intervention, and self-isolation after recovery. As a major transportation hub of China, Wuhan faced increased difficulties in outbreak control. Efforts to control COVID-19 need to take into account globalization processes.[@bib32] Severe male patients with heart injury, hyperglycemia, and high-dose corticosteroid use may have a high risk of death.Clinical implicationsMale sex, older age, leukocytosis, high LDH level, cardiac injury, and hyperglycemia may be associated with the fatal outcome of patients with severe COVID-19. High-dose corticosteroid use was related to a high risk of death.
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[^2]: Data are expressed as median (IQR), n (%), or n of N (%), where N is the total number of patients with available data. *P* values comparing nonsevere cases and severe cases are from χ^2^ test, Fisher exact test, or Mann-Whitney *U* test.

[^3]: *ACEI/ARB*, Angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker; *IQR*, interquartile range.

[^4]: Days from December 1, 2019, to the date of onset.

[^5]: Equivalent doses of prednisone.

[^6]: Data are expressed as median (IQR), n (%), or n of N (%), where N is the total number of patients with available data. *P* values comparing nonsevere cases and severe cases are from χ^2^ test, Fisher exact test, or Mann-Whitney *U* test.

[^7]: *IQR*, Interquartile range.

[^8]: SARS-CoV-2 nucleic acid test was performed preadmission.

[^9]: Data are expressed as median (IQR), n (%), or n of N (%), where N is the total number of patients with available data. *P* values comparing nonsevere cases and severe cases are from χ^2^ test, Fisher exact test, or Mann-Whitney *U* test.

[^10]: *DIC*, Diffuse intravascular coagulation; *IQR*, interquartile range.

[^11]: *P* values are from Cox proportional hazards regression model. The final model was adjusted for sex, age, blood leukocyte count, LDH, cardiac injury, hyperglycemia, and administration of corticosteroids, lopinavir/ritonavir, and umifenovir.

[^12]: Low dose of steroid indicates that the maximum dose was \<1 mg/kg/d prednisone.

[^13]: High dose of steroid indicates that the maximum dose was equivalent to or more than 1 mg/kg/d prednisone.
